PT1002108E - Utilizacao de ligandos de mhc classe ii como adjuvantes para vacinacao e de lag-3 no tratamento de cancro - Google Patents

Utilizacao de ligandos de mhc classe ii como adjuvantes para vacinacao e de lag-3 no tratamento de cancro

Info

Publication number: PT1002108E
Authority: PT; Portugal
Prior art keywords: mhc class; lag; advocacy; vaccination; ligands
Prior art date: 1997-07-25

Application number

PT98945090T

Other languages

English (en)

Inventor

Frederique Triebel

Original Assignee

Applied Research Systems

Roussy Inst Gustave

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-25

Filing date

1998-07-23

Publication date

2006-09-29

1998-07-23 Application filed by Applied Research Systems, Roussy Inst Gustave filed Critical Applied Research Systems

2006-09-29 Publication of PT1002108E publication Critical patent/PT1002108E/pt

Links

239000003446 ligand Substances 0.000 title abstract 4
102000017578 LAG3 Human genes 0.000 title abstract 3
101150030213 Lag3 gene Proteins 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
238000002255 vaccination Methods 0.000 title 1
102000043131 MHC class II family Human genes 0.000 abstract 3
108091054438 MHC class II family Proteins 0.000 abstract 3
239000000427 antigen Substances 0.000 abstract 3
102000036639 antigens Human genes 0.000 abstract 3
108091007433 antigens Proteins 0.000 abstract 3
230000028993 immune response Effects 0.000 abstract 2
230000000145 adjuvantlike effect Effects 0.000 abstract 1
238000002619 cancer immunotherapy Methods 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT98945090T 1997-07-25 1998-07-23 Utilizacao de ligandos de mhc classe ii como adjuvantes para vacinacao e de lag-3 no tratamento de cancro PT1002108E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP97401800A EP0893507A1 (en)	1997-07-25	1997-07-25	Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment

Publications (1)

Publication Number	Publication Date
PT1002108E true PT1002108E (pt)	2006-09-29

Family

ID=8229825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT98945090T PT1002108E (pt)	1997-07-25	1998-07-23	Utilizacao de ligandos de mhc classe ii como adjuvantes para vacinacao e de lag-3 no tratamento de cancro

Country Status (19)

Country	Link
US (2)	US6410509B1 (pt)
EP (3)	EP0893507A1 (pt)
JP (1)	JP4723722B2 (pt)
KR (1)	KR100603075B1 (pt)
CN (1)	CN1184320C (pt)
AT (2)	ATE478956T1 (pt)
AU (1)	AU753738B2 (pt)
BR (1)	BR9811037A (pt)
CA (2)	CA2732570C (pt)
DE (2)	DE69841866D1 (pt)
DK (1)	DK1002108T3 (pt)
EA (3)	EA003740B1 (pt)
EE (1)	EE200000039A (pt)
ES (1)	ES2262242T3 (pt)
IL (2)	IL134212A0 (pt)
NO (1)	NO20000378L (pt)
PT (1)	PT1002108E (pt)
UA (1)	UA75322C2 (pt)
WO (1)	WO1999004810A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1295895B1 (en) *	2001-09-19	2011-08-10	Institut Gustave Roussy	Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
US20060240024A1 (en)	2003-02-28	2006-10-26	The Johns Hopkins University	T cell regulation
KR20050082389A (ko) *	2004-02-18	2005-08-23	메덱스젠 주식회사	직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr)	2004-04-13	2008-02-22	Immutep	Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (en) *	2005-10-19	2007-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2044949A1 (en) *	2007-10-05	2009-04-08	Immutep	Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2011031139A1 (en)	2009-09-09	2011-03-17	Universiteit Utrecht Holding B.V.	An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar)	2009-11-13	2014-09-16	Laboratories Leti S L Unipersonal	استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
JP5986576B2 (ja)	2010-11-10	2016-09-06	ラボラトリオスレティ，エセ．エレ．	新規アジュバント
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
CA2935423C (en)	2014-01-24	2023-11-07	Dana-Farber Cancer Institute, Inc.	Antibody molecules to pd-1 and uses thereof
CN103751778B (zh) *	2014-01-28	2016-09-28	复旦大学	3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
WO2015138920A1 (en)	2014-03-14	2015-09-17	Novartis Ag	Antibody molecules to lag-3 and uses thereof
US10537626B2 (en)	2014-10-07	2020-01-21	Cytlimic Inc.	HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
US9827308B2 (en)	2014-12-10	2017-11-28	Wisconsin Alumni Research Foundation	Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
JP6898225B2 (ja)	2015-03-09	2021-07-07	サイトリミック株式会社	Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3797794A1 (en) *	2015-04-07	2021-03-31	Cytlimic Inc.	Medicine comprising a toll like receptor 3 agonist and a lag-3 protein
EP3294324A1 (en)	2015-05-13	2018-03-21	Agenus Inc.	Vaccines for treatment and prevention of cancer
EP3744340A3 (en)	2015-07-16	2021-03-03	Biokine Therapeutics Ltd.	Compositions and methods for treating cancer
ES2878188T3 (es)	2015-07-29	2021-11-18	Novartis Ag	Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US10265379B2 (en)	2015-09-16	2019-04-23	Annabelle Rodriguez Oquendo	Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
EP3349790A1 (en)	2015-09-18	2018-07-25	Rijksuniversiteit Groningen	Long chain inulin for stimulating an immune response
AU2017342189B2 (en)	2016-10-11	2023-09-21	Nec Corporation	Medicine
CN108204958A (zh) *	2016-12-19	2018-06-26	伊缪泰普有限公司	结合测定
KR20210005646A (ko)	2018-04-26	2021-01-14	아게누스 인코포레이티드	열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
US20230057310A1 (en) *	2018-09-27	2023-02-23	Genocea Biosciences, Inc.	Treatment methods
JP2020138940A (ja)	2019-02-28	2020-09-03	テルモ株式会社	治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT88641B (pt) *	1987-10-02	1993-04-30	Genentech Inc	Metodo para a preparacao de uma variante de adesao
WO1990001870A1 (en) *	1988-08-22	1990-03-08	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	Retroviral vectors expressing soluble cd4; a gene therapy for aids
JPH02231083A (ja) *	1988-08-31	1990-09-13	Eisai Co Ltd	組換ナチュラルキラー細胞活性化因子
IL93599A0 (en) *	1989-03-03	1990-12-23	Microgenesys Inc	Kit and/or composition for the prevention or treatment of aids
EP0394827A1 (en) *	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
FR2656800B1 (fr) *	1990-01-08	1992-05-15	Roussy Inst Gustave	Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) *	1991-03-07	1998-12-22	The General Hospital Corporation	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO1994016737A1 (en) *	1993-01-26	1994-08-04	Weiner David B	Compositions and methods for delivery of genetic material
SE510135C2 (sv) *	1994-05-05	1999-04-19	Berol Nobel Ab	Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
DK0758383T3 (da) *	1994-05-06	2007-05-29	Roussy Inst Gustave	Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
CA2194488A1 (en) *	1994-08-05	1996-02-15	Tod Paul Holler	Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
PL320610A1 (en) *	1994-12-07	1997-10-13	Hoffmann La Roche	Fragments of monoclonal antibodies of immunosuppressive activity
JPH10511652A (ja) *	1994-12-23	1998-11-10	ラボラトワール・オン・ソシエテ・アノニム	炎症性疾患の予防および／または治療に対するｍｈｃ−ｉｉ結合および／またはｍｈｃ−ｉｉ模倣分子の使用
ES2191784T3 (es) *	1995-12-28	2003-09-16	Univ Johns Hopkins Med	Vacunas de tumores de citocinas paracrinas alogenicas.

1997
- 1997-07-25 EP EP97401800A patent/EP0893507A1/en not_active Withdrawn
1998
- 1998-07-23 EA EA200000161A patent/EA003740B1/ru not_active IP Right Cessation
- 1998-07-23 CN CNB988075474A patent/CN1184320C/zh not_active Expired - Lifetime
- 1998-07-23 AT AT06008545T patent/ATE478956T1/de not_active IP Right Cessation
- 1998-07-23 CA CA2732570A patent/CA2732570C/en not_active Expired - Lifetime
- 1998-07-23 PT PT98945090T patent/PT1002108E/pt unknown
- 1998-07-23 UA UA2000020976A patent/UA75322C2/uk unknown
- 1998-07-23 AT AT98945090T patent/ATE324455T1/de active
- 1998-07-23 DK DK98945090T patent/DK1002108T3/da active
- 1998-07-23 EA EA200300092A patent/EA200300092A1/ru unknown
- 1998-07-23 DE DE69841866T patent/DE69841866D1/de not_active Expired - Lifetime
- 1998-07-23 AU AU92547/98A patent/AU753738B2/en not_active Expired
- 1998-07-23 EP EP98945090A patent/EP1002108B1/en not_active Expired - Lifetime
- 1998-07-23 EA EA200200565A patent/EA005405B1/ru not_active IP Right Cessation
- 1998-07-23 EE EEP200000039A patent/EE200000039A/xx unknown
- 1998-07-23 DE DE69834330T patent/DE69834330T2/de not_active Expired - Lifetime
- 1998-07-23 IL IL13421298A patent/IL134212A0/xx unknown
- 1998-07-23 BR BR9811037-3A patent/BR9811037A/pt not_active IP Right Cessation
- 1998-07-23 EP EP06008545A patent/EP1698701B1/en not_active Expired - Lifetime
- 1998-07-23 CA CA2293805A patent/CA2293805C/en not_active Expired - Lifetime
- 1998-07-23 WO PCT/EP1998/004621 patent/WO1999004810A2/en not_active Ceased
- 1998-07-23 JP JP2000503862A patent/JP4723722B2/ja not_active Expired - Lifetime
- 1998-07-23 ES ES98945090T patent/ES2262242T3/es not_active Expired - Lifetime
- 1998-07-23 KR KR1020007000265A patent/KR100603075B1/ko not_active Expired - Fee Related
2000
- 2000-01-24 IL IL134212A patent/IL134212A/en not_active IP Right Cessation
- 2000-01-25 NO NO20000378A patent/NO20000378L/no not_active Application Discontinuation
- 2000-01-27 US US09/492,113 patent/US6410509B1/en not_active Expired - Lifetime
2002
- 2002-01-10 US US10/041,600 patent/US7109026B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA005405B1 (ru)	2005-02-24
EA200000161A1 (ru)	2000-10-30
EP0893507A1 (en)	1999-01-27
KR20010021706A (ko)	2001-03-15
KR100603075B1 (ko)	2006-07-20
WO1999004810A2 (en)	1999-02-04
JP4723722B2 (ja)	2011-07-13
EA003740B1 (ru)	2003-08-28
DE69834330D1 (de)	2006-06-01
ATE478956T1 (de)	2010-09-15
DK1002108T3 (da)	2006-08-21
CA2293805A1 (en)	1999-02-04
WO1999004810A3 (en)	1999-07-08
EP1002108A2 (en)	2000-05-24
EP1698701A1 (en)	2006-09-06
IL134212A (en)	2012-03-29
EP1002108B1 (en)	2006-04-26
US6410509B1 (en)	2002-06-25
CA2732570C (en)	2014-11-18
ATE324455T1 (de)	2006-05-15
AU9254798A (en)	1999-02-16
CN1265149A (zh)	2000-08-30
BR9811037A (pt)	2000-08-01
EP1698701B1 (en)	2010-08-25
EA200300092A1 (ru)	2003-06-26
UA75322C2 (en)	2006-04-17
HK1030014A1 (en)	2001-04-20
DE69841866D1 (de)	2010-10-07
CN1184320C (zh)	2005-01-12
NO20000378D0 (no)	2000-01-25
EE200000039A (et)	2000-10-16
IL134212A0 (en)	2001-04-30
EA200200565A1 (ru)	2002-10-31
AU753738B2 (en)	2002-10-24
US20020192195A1 (en)	2002-12-19
NO20000378L (no)	2000-01-25
JP2001510806A (ja)	2001-08-07
CA2732570A1 (en)	1999-02-04
CA2293805C (en)	2011-05-03
DE69834330T2 (de)	2007-03-29
ES2262242T3 (es)	2006-11-16
US7109026B2 (en)	2006-09-19

Publication	Publication Date	Title
IL134212A0 (en)	2001-04-30	Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
DK0490077T3 (da)	1998-01-26	Antisense-oligonukleotider til behandling af cancer
ES2160707T3 (es)	2001-11-16	Composiciones que comprenden agentes deteriorantes del adn y p53.
SI2371391T1 (sl)	2014-12-31	Terapevtska uporaba protiteles anti-CS1
BR9715022A (pt)	2001-09-18	Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
BR9106114A (pt)	1993-03-09	Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
PL2301576T3 (pl)	2013-02-28	Zastosowanie terapeutyczne przeciwciał anty-CS1
DK0841949T3 (da)	2006-08-21	Anvendelse af saccharid-konjugater
IL134345A0 (en)	2001-04-30	Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
EP0719150A4 (en)	1998-07-29	CELLULAR VACCINE AND METHODS OF USE FOR TREATING MALIGNAS, SOLID TUMORS
DE69320646D1 (de)	1998-10-01	Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
PT1173201E (pt)	2005-08-31	Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
PT845998E (pt)	2002-04-29	Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado
BR9913718A (pt)	2001-05-29	Processo e composição farmacêutica ou veterinária para inibição profilática ou terapêutica de um material ou substância tóxica em um paciente animal humano ou não-humano, e, uso de um dendrìmero aniÈnico ou catiÈnico
PT1237562E (pt)	2005-03-31	Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
FI900372A7 (fi)	1990-07-27	Aryyli- ja heteroaryylietanoli-pyridyylialkyyliamiinit, menetelmä niiden valmistamiseksi ja niiden käyttö suoritusta edistävinä aineina eläimillä ja liikalihavuuden hoitoon käytettävinä aineina
EP0860179A3 (de)	1999-12-15	Vorrichtung zur therapeutischen oder kosmetischen Behandlung mit Licht
BRPI0409870A (pt)	2006-05-16	uso de irinotecano para tratamento de cáncer de mama resistente
DE59712247D1 (de)	2005-04-28	Mammakarzinom-assoziiertes gen
PT979093E (pt)	2002-06-28	Agente viral terapeutico que interrompe o desenvolvimento de tumores
TR199901998T2 (xx)	1999-11-22	9,10-sekokolesta-5,7,10(19)-triyen-1,3-diyol veya alfakasidol�n kullan�m�.
BRPI0512889A (pt)	2008-04-15	uso de um anticorpo ou um fragmento de ligação de antìgeno deste e de pelo menos um agente anticáncer, preparação combinada, e, métodos de tratamento de cáncer, e de leucemia
ATE79759T1 (de)	1992-09-15	Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.